Michiel Tent summarises 6 abstracts from the MS Virtual 2020 and its Encore Event:
- EDSS and age are risk factors for severe COVID-19 in MS patients
Louapre C. MSVIRTUAL2020, Abstract SS02.06. - Brain alterations at onset of first demyelinating event
Collorone S. MSVIRTUAL2020, Abstract LB01.04. - Amantadine, modafinil, and methylphenidate for MS-related fatigue
Nourbakhsh B, et al. MSVIRTUAL2020, Abstract PS13.03. - Masitinib possible new treatment of progressive MS
Vermersch P, et al. MSVIRTUAL2020, Abstract FC04.01. - No new safety signals in ofatumumab open-label data
Cross AH, et al. MSVIRTUAL2020, Abstract P0234. - The MS prodrome
Tremlett H. MSVIRTUAL2020, Abstract PL01.01.
- EDSS and age are risk factors for severe COVID-19 in MS patients
Posted on
Previous Article
« Experts recommend three dosing protocols for medical cannabis when treating chronic pain Next Article
Numerous drugs can spawn a broad range of arrhythmias »
« Experts recommend three dosing protocols for medical cannabis when treating chronic pain Next Article
Numerous drugs can spawn a broad range of arrhythmias »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
December 9, 2021
Dynamic scoring system aids decision to switch MS therapies early
September 10, 2020
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
August 22, 2022
Teriflunomide in children with MS: final results of TERIKIDS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy